Skip to main content
Log in

Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran

  • Internal Medicine
  • Original Article Haemostasis/Thrombosis
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Objective

The haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are rare disorders characterised by intravascular platelet aggregation and widespread thrombus formation in the microcirculation resulting in tissue ischaemia. A retrospective analysis was carried out in 136 patients with HUS or TTP hospitalized from April 1991 through March 2004 in three tertiary referral hospitals of Shiraz (the largest city in southern Iran) to evaluate the epidemiological aspects, clinical characteristics and laboratory findings of the two diseases.

Methods

One hundred and one cases of HUS (49 females and 52 males) and 35 cases of TTP (21 females and 14 males) were identified. The mean age was 3.5 years for HUS, 30.8 years for TTP.

Results

The mean annual incidence rate of HUS decreased approximately 30-fold throughout the observed period, while the incidence rate of TTP increased approximately 6-fold. A seasonal pattern was noted for both TTP and HUS, with the highest incidence during the summer months. Twenty patients with HUS and 16 patients with TTP died, resulting in case fatality rates of 19.8% and 45.7%, respectively. No prognostic factor was identified for TTP, whereas signs of neurological impairment and high leucocyte counts had an adverse effect on the prognosis of HUS patients.

Conclusions

This study shows that, in contrast to other countries, the incidence rate of HUS shows a decreasing trend in southern Iran probably related to the prevention of gastrointestinal diarrhoeal infections (especiallyEscherichia coli 0157:H7) and to their improved management. The incidence of TTP is increasing in Iran as in other countries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bell WR. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: frequency, pathogenesis, and meaning.Semin Hematol 1997; 34: 134–9.

    PubMed  CAS  Google Scholar 

  2. Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.Best Pract Res Clin Haematol 2001; 14: 437–54.

    Article  PubMed  CAS  Google Scholar 

  3. Moake JL. Thrombotic thrombocytopenic purpura: the systemic clumping “plague”.Annu Rev Med 2002; 53: 75–88.

    Article  PubMed  Google Scholar 

  4. Tsai HM, Lian EC. Antibodies to von Willebrand factorcleaving protease in acute thrombotic thrombocytopenic purpura.N Engl J Med 1998; 339: 1585–94.

    Article  PubMed  CAS  Google Scholar 

  5. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.N Engl J Med 1998; 339: 1578–84.

    Article  PubMed  CAS  Google Scholar 

  6. Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States-analysis of national mortality data, 1968–1991.Am J Hematol 1995; 50: 84–90.

    Article  PubMed  CAS  Google Scholar 

  7. Miller DP, Kaye JA, Shea K, et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome.Epidemiology 2004; 15: 208–15.

    Article  PubMed  Google Scholar 

  8. Cummings KC, Mohle-Boetani JC, Werner SB, Vugia DJ. Population-based trends in pediatric hemolytic uremic syndrome in California, 1994–1999: substantial underreporting and public health implicationsAm J Epidemiol 2002; 155: 941–8.

    Article  PubMed  Google Scholar 

  9. Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.N Engl J Med 1991; 325: 393–7.

    PubMed  CAS  Google Scholar 

  10. Karimi M, Sabzi A, Peyvandi F, Mannucci PM. Changing epidemiology of the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran.J Thromb Haemost 2006; 4: 701–2.

    Article  PubMed  CAS  Google Scholar 

  11. Martin DL, Mac Donald KL, White KE, Soler JT, Osterholm MT. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota.N Engl J Med 1990; 323: 1161–7.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mehran Karimi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karimi, M., Sabzi, A., Peyvandi, F. et al. Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran. Int Emergency Med 1, 35–39 (2006). https://doi.org/10.1007/BF02934718

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02934718

Key words

Navigation